Ближайший уровень поддержки по SPY – 189.50 уровень сопротивления – 191.00



AVGO возможен откат вверх от 71

FFIV продажа ниже 107 выше 108 покупка

SVXY смотрим на откат вверх выше 62

SM при удержании 60,50 покупка

LRCX смотрим на покупку выше 66

CAVM следим за акцией

CPA продажа ниже 100,50

Gapping up/down: APL and ATLS +13% on M&A related news; Ebola related names trading higher, SPLK +2% on upgrade; LAD -10% and GY -3% after earnings, JCP and CLF -1% on dg's Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: MDXG +4.3%

M&A news: APL +12.8% (Targa Resources Partners and Targa Resources Corp. (TRGP) to acquire Atlas Pipeline Partners, L.P. (APL) and Atlas Energy, L.P. (ATLS)), ATLS +12.5%, CSX +9.2% (was approached for M&A deal with Canadian Pacific (CP) but CSX refused it, according to reports), TRGP +1.9%.

Select EU related names showing strength: NOK +2.3%, HSBC +2.1%, SAN +1.9%, YNDX +1.4%, RBS +1.1%, DB +0.9%

Select Ebola related stocks trading higher: IBIO +78.9% (outpacing strength seen this morning in most Ebola related names; checking around for company specific catalyst), HEB +20.6%, APT +18.7% (masks), LAKE +17.5% (masks), NLNK +4.7%, TKMR +4.1%, MLNX +2.2%, INO +1.1%, BCRX +0.7%, SIGA +0.7%

Select metals/mining stocks trading higher: MT +5%, RIO +4%, VALE +3.2%, BHP +2.7%, AU +2.3%, IAG +1.3%, GDX +1.3%, IAG +1.3%, ABX +1%

Select oil/gas related names showing strength: PBR +6.7%, SDRL +5.7%, TOT +1.6%, RIG +1.4%

Other news: DRL +66.4% (wins in Puerto Rico tax case), AHPI +7.6% (cont momentum), SHLD +4.9% (Kmart investigating payment system intrusion), AIXG +4.8% (Allianz Global Investors discloses 10.03% passive stake in 13G filing), KSU +2.6% (CSX peer), PXD +2.5% (Reliance Industries may sell PXD joint venture for $4.5 bln, according to reports), STO +1.5% (sells 15.5% share in Shah Deniz to Petronas for $2.2 bln), TASR +1.4% (announced four international orders — Australia, France, the UK, and Poland — for TASER brand next generation Smart Weapons).

Analyst comments: FOMX +8.3% (initiated with an Overweight at Barclays; initiated with a Outperform at Oppenheimer), GOLD +4.8% (upgraded to Buy from Neutral at UBS), TKAI +3.2% (initiated with an Outperform at William Blair), PRQR +3.2% (initiated with a Buy at H.C. Wainwright), SPWR +3% (upgraded to Outperform from Mkt Perform at Raymond James), SPLK +2.4% (upgraded to Outperform from Mkt Perform at William Blair), AZN +2.3% (upgraded to Buy from Hold at Jefferies), INFY +2% (upgraded to Buy form Hold at Deutsche Bank), TILE +2% (upgraded to Overweight from Equal Weight at Barclays), OUTR +1.9% (upgraded to Neutral from Sell at B. Riley & Co), SFUN +1.4% (upgraded to Buy from Hold at Deutsche Bank), TMUS +0.7% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: LAD -10.5%, GY -2.9%

M&A news: DG -1.2% (receives second request from FTC, as expected, regarding proposed acquisition of Family Dollar (FDO))

Other news: GTAT -23.5% (cont vol pre-mkt), LAD -10.5% (still checking), SFLY -7.9% (PE firm Silver Lake abandons attempt to acquire and combine Shutterly and Snapfish, according to reports), LUX -7.2% (Enrico Cavatorta to submit to the Board his resignation as CEO, also downgraded to Neutral from Buy at Citigroup), GPRO -1.8% (cont vol pre-mket), MBLY -1.2% (cautious Barrons mention)

Analyst comments: STM -2.3% (downgraded to Neutral from Overweight at JP Morgan, downgraded to Underweight from Equal-Weight at Morgan Stanley), NGD -1.8% (downgraded to Neutral from Overweight at JP Morgan), JCI -1.2% (downgraded to Outperform at RBC Capital Mkts), CLF -1% (downgraded to Neutral from Overweight at JP Morgan), JCP -1% (downgraded to Sell from Neutral at UBS), CME -0.5% (downgraded to Market Perform from Outperform at Wells Fargo)

Оригинал статьи: gtstocks.com/analytics-13-10-2014.html

Ближайший уровень поддержки по SPY – 191.75 уровень сопротивления – 192.50



LAKE следим за недавним IPO

SRTY покупка выше 48

ERY покупка при удержании 20

SCO покупка выше 35.50

ERX смотрим на дальнейшее падение

APC ждем разворот выше 52

FSLR ниже 56 продажа, выше покупка

GPS продажа ниже 65.50

URI следим на открытии, возможен откат вверх

ROK покупка при удержании 103

CXO продажа ниже 109.50

EXP покупка при удержании 87

Gapping up/down: INFY +5% after earnings, EXAX +36% after positive CMS determination over Cologuard; MCHP -11%, MTW -9%, and JNPR -7% after earnings, Semis, oil and gold stocks trading lower Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: INFY +5.6%, HELE +3%, PLUG +2.7%

Other news: EXAS +35.8% (positive CMS determination over Cologuard), APT +26% (following 27% move higher yesterday with ongoing Ebola fears), SCMP +19.2% (Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA), ALXA +16.8% (provided update on ADASUVE U.S. Commercial Progress; Alexza shipped 32,278 units in the third quarter, completing the ADASUVE initial product inventory stocking), CVEO +12.6% (Greenlight capital discloses 9.99% active stake in 13D filing), STV +6.9% (cont volatility pre-mkt), ISIS +5.3% (reports data from ISIS-SMN Rx Phase 2 studies in infants and children with spinal muscular atrophy), VNET +4.7% (establishes joint venture with Foxconn (FXCNY)), ARIA +3.7% (announced that Pharmacovigilance Risk Assessment Committee of EMA concluded review of Iclusig and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indication), BX +2.7% (planning advisory spin-off, according to reports), ECOL +2.5% (to replace MEAS in the S&P SmallCap 600), OXLC +2.1% (adopted repurchase program of up to $35 mln worth of common stock), KGJI +1.6% (announces initial shipment of 24-karat gold jewelry product samples to Middle East)

Analyst comments: NDLS +0.9% (initiated with an Outperform at BMO Capital Mkts ), WDC +0.7% (initiated with a Buy at Jefferies), NRP +0.7% (upgraded to Outperform from Market Perform at Wells Fargo), BUD +0.5% (added to Conviction Buy List at Goldman)

Gapping down
In reaction to disappointing earnings/guidance: PKT -25.1%, VOXX -16.4%, SZMK -13.9%, MCHP -11.1%, KN -10.8%, MTW -8.9%, JNPR -7%, JOEZ -5%, FDO -1%

Select Semi names showing weakness: NXPI -4.4%, ATML -4.1%, STM -3.9%, LLTC -3.1%, ALTR -2.7%, ASML -2.1%, AVGO -2%, MU -1.9%

Select metals/mining stocks trading lower: CVE -3.3%, RIO -2.2%, GOLD -1.9%, AU -1.2%, GFI -1%

Select oil/gas related names showing early weakness: SDRL -2.5%, STO -2.2%, BHP -2.1%, TOT -1.7%, RIG -1.6%, HAL -0.4%

Other news: GTAT -29.5% (reportedly looking to close down its saphire business, according to court documents), TSLA -6.2% (following run-up into Model D event, also neg mention on Mad Money), MBLY -4.8% (news that new Tesla (TSLA) Model D will have self driving features), TKMR -3.4% (cont volatility), THLD -2.3% (disclosed that it has licensed rights to a development program from the University of Auckland based on the clinical-stage oncology compound Hypoxin; co expects to initiate a Phase 2 study of Hypoxin), RDS.A -2.3% (still checking), PTCT -2.3% (prices 3 mln shares of common stock at $36.25), SM -1.9% (sees Q3 production of 13.1 MMBOE, or 142.5 MBOE/d, at low end of previously provided guidance), SYMC -1.6% (announces new strategy to fuel growth and plans to separate into two public companies), GPRO -1.3% (founder Silicon Valley Community Foundation filed 13D), YHOO -1.2% (still checking), AMGN -1.1% (BiTE Immunotherapy Blinatumomab receives FDA Priority Review designation in acute lymphoblastic leukemia)

Analyst comments: BDSI -3.4% (downgraded to Hold from Buy at ROTH Capital), NDSN -3.4% (downgraded to Hold from Buy at BB&T Capital Mkts), GRPN -3.1% (downgraded to Sell from Equal Weight at Evercore), JCP -2.5% (downgraded to Sell at Maxim Group), ICLR -1.8% (downgraded to Neutral from Buy at ISI Group), BTI -1.2% (downgraded to Sell from Neutral at Goldman)

Оригинал статьи: gtstocks.com/analytics-10-10-2014.html

Ближайший уровень поддержки по SPY – 196.00 уровень сопротивления – 197.25



Поздравляем всех с началом сезона отчетов. Вчера после закрытия рынка отчиталась положительно Alcoa Inc. Инвесторы могут положительно настроиться на рост рынка в ближайшие дни.

Alcoa — американская металлургическая фирма, 3-ий по величине производитель алюминия. Трехмесячный результат о деятельности данной фирмы, кой выходит 8 октября окажет мощное воздействие на цену акций.

GILD продажа от 109

AMGN продажа от 140

SSO продажа от 117

GOLD продажа ниже 70

URI покупка выше 103

DUST смотрим на лонг

Gapping up/down: RT +18% and AA +1.6% after earnings; AUXL +11% after merger ENDP, AGN +2.4% after upgrade; GPS -10% after guiding and CEO transition news, VOD -3% after dg Price: null Change: null

Gapping up
In reaction to strong earnings/guidance/SSS: RT +18.2%, DRWI +7.7%, EXAR +7.7%, LB +2.9%, AGN +2.4%, ZUMZ +1.8%, AA +1.6%, PEP +1.6%

M&A news: AUXL +10.7% (Endo (ENDP) to acquire Auxilium Pharmaceuticals in a cash and stock transaction for ~$2.6 bln, or $33.25 per share)

Select metals/mining stocks trading higher: PAAS +1.9%, SLV +1.6%, SSRI +1.2%, CDE +1.2%, AU +1%, HMY +0.9%, ABX +0.9%, GLD +0.7%, GDX +0.6%

Other news: SFXE +10.1% (announces that Chairman and CEO Robert F.X. Sillerman completed the purchase of 575k shares today), GTAT +10% (cont volatility), UAL +4.7% (reported September 2014 consolidated traffic decreased 0.2%, consolidated capacity decreased 0.4%), BLDP +4.4% (Ballard Power announces multi-year fuel cell supply agreement with Plug Power (PLUG) for forklift market), CGG +3.3% (reports vessel utilization and fleet allocation updates for third quarter 2014), NUAN +1.9% (rumors on Carl Icahn tweet — potential acquistion target), PLUG +1.3% (Ballard Power announces multi-year fuel cell supply agreement with Plug Power (PLUG) for forklift market), GNC +1.3% (positive mention on Wednesday's Mad Money)

Analyst comments: UAL +4.7% (added to Global Focus list at Credit Suisse), LPSN +2.6% (upgraded to Outperform from Neutral at Credit Suisse), AGN +2.4% (initiated with a Buy at Deutsche Bank), UTI +0.9% (upgraded to Outperform from Market Perform at Wells Fargo), TSLA +0.8% (ahead of D-day event, also added to Global Focus list at Credit Suisse), ROYT +0.8% (upgraded to Buy at Stifel), JCP +0.6% (Hearing defended at Piper Jaffray--reits Overweight rating), IIVI +0.6% (upgraded to Buy at DA Davidson)

Gapping down
In reaction to disappointing earnings/guidance: ARCW -18%, KFX -14.8%, GPS -9.7%, (also announces CEO transition news), EOPN -8.9%, DEST -1.4%,.

M&A news: ENDP -0.7% (Endo to acquire Auxilium Pharmaceuticals)

Select financial related names showing weakness: DB -3.2%, BCS -2.7%, SAN -2.7%, RBS -2%, HSBC -1.8%, LYG -1.4%

Select oil/gas related names showing early weakness: TOT -2.7%, RDS.A -2.4%, BP -1.4%, STO -1.3%, STO -1.3%, RIG -1%

Other news: PT -4.4% (still checking), ARWR -3.8% (higher following Deutsche Bank analyst appearance on CNBC defending the company, said today's sell off was over done), ONTX -3.2% (co filed for a $100 mln mixed securities shelf offering; co also filed for a 228,647 share common stock offering by selling shareholders), STV -2.2% (disclosed further update on its asset restructuring), X -0.8% (CAD $ 185 mln debtor financing facility approved, according to reports), TWTR -0.7% (Twitter's exec Vivian Schiller to leave the company with part of media consolidation, according to reports)

Analyst comments: HUB.B -5% (downgraded to Perform at Oppenheimer), ARWR -3.8% (downgraded to Sector Perform at RBC Capital Mkts), VOD -3.1% (downgraded to Reduce from Neutral at Nomura), ERIC -1.9% (reinstated with a Underperform at BofA/Merrill)

Оригинал статьи: gtstocks.com/analytics-09-10-2014.html

Ближайший уровень поддержки по SPY – 193.25 уровень сопротивления – 194.00



CAMP продажа от 20

SRTY смотрим на лонг

URI смотрим на продажу

EMES продажа ниже 95

TCS покупка от 16.50

Gapping up/down: COST +2% and YUM +1% after earnings, COTY +4% after upgrade; SAVE -3% and MON -2% after earnings/guidance, SAP -3% after reports of Job freeze, GPRO -2% after dg Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: COST +2.4%, YUM +1.3%

M&A news: TST +5% (to acquire BoardEx for ~$21 mln), SYMC +3.4% (may consider splitting up security and storage units, according to reports), AGN +1.9% (VRX and Pershing Square intend to increase bid for co), VRX +1.4% (co and Pershing Square intend to increase bid for Allergan (AGN)

Select financial related names showing strength: NBG +2%, ING +1.4%, SAN +1.4%, UBS +1.1%, HSBC +0.9%

Select metals/mining stocks trading higher: HL +3%, GFI +2.2%, AUY +1.6%, ABX +1.4%, IAG +1.3%, SLW +1.3%, GOLD +1.2%, SLV +1%, GDX +0.9%

Other news: GTAT +21.5% (seeing reports that co's first bankruptcy hearing has been scheduled for Thursday), SCOK +11.7% (issues update on construction and financing of underground Syngas Project), WYY +8.6% (receives 4 new federal contract awards; contract has period of performance of one year and total ~$2.7 mln), DRL +6.7% (disclosed the appointment of Nancy Reinhard as acting CFO), TST +5% (to acquire BoardEx for ~$21 mln), CMRX +4.9% (shows potential survival benefit in Adenovirus infection), PAH +3.7% (Pershing square disclosed a 26.1% active stake), TASR +3.7% (body camera momentum builds as adoption of AXON and EVIDENCE.com accelerates), OXGN +3% (announced first patient enrolled in Phase 1b/2 Study of Fosbretabulin combined with Pazopanib in patients with advanced recurrent ovarian cancer), MBLY +2.9% (ahead of TSLA event tomorrow), TKMR +2.5% (cont momentum/Ebola play), JCP +2.3% (ahead of anaylst day), ORAN +1.4% (in talks with other cos to create Netflix (NFLX) like streaming service, according to reports), BCRX +1.1% (present clinical trial results related to investigational drug RAPIVAB at the IDWeek Conference October 8-12)

Analyst comments: COTY +4.2% (upgraded to Neutral from Sell at B. Riley & Co), GLUU +2.3% (upgraded to Buy from Hold at The Benchmark Company), CMI +0.9% (initiated with a Buy at Stifel), LEAF +0.9% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: TILE -17.9%, (announces expansion of credit facility, planned bond redemption, share repurchase program ), SAVE -3.2%, (co sees Q3 adjusted operating margin in lower half of previous guidance range) MON -1.6%, RPM -1%, ASX -0.8%,.

Other news: RDY -4% (weak markets in India overnight), SAP -3.5% (reports suggesting job freeze until 2015 ), ICPT -3.2% (co decides not to present FLINT data at AASLD), RIO -2.1% (may still go after a defense deal with Anglo American (AAUKY), according to reports), INFY -1.5% (weak markets in India overnight), ALU -1.1% (still checking), GSK -0.8% (corruption allegations, according to reports out intraday), AZN -0.8% (may be in sympathy with GSK)

Analyst comments: SSNI -2.3% (downgraded to Neutral from Buy at Goldman), GPRO -2.2% (downgraded to Neutral from Overweight at Piper Jaffray), ARP -1.6% (initiated with a Mkt Perform at Raymond James)

Оригинал статьи: gtstocks.com/analytics-08-10-2014.html

Ближайший уровень поддержки по SPY – 195.00 уровень сопротивления – 196.00



LRCX продажа от 75

WLP покупка от 119

DWRE продажа ниже 58

Gapping up/down: SIMO +15% and CAMP +7% after earnings, FEYE +6% after new partnerships; GMCR +2% on upgrade at GS; SODA and TCS -15% after earnings/guidance; LVS -3% after dg Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: SIMO +14.9%, CAMP +7.2%, ISCA +4.9%, NLNK +1.9%, IDT +0.6%

Select Ebola related names showing strength: CMRX +3.9%, TKMR +3.4%, LAKE +2.8%

Select metals/mining stocks trading higher: IGLD +2.5%, IAG +0.8%, CDE +0.8%, SVM +0.6%

Other news: GTAT +15% (modest retracement following yesterday's massive decline), MAGS +15% (receives $8.2 mln of new orders; majority of the contracts are for expansions, changes and upgrades of existing homeland security installations in Israel), XCO +10.6% (announces sale of interests in Compass Production Partners), BCLI +9% (FDA grants fast track designation to NurOwn for the treatment of ALS), OXGN +8.3% (announced that data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on November 9 at the International Gynecologic Cancer Society), GSAT +7.1% (issues statement in response to Kerrisdale Capital presentation), FEYE +5.8% (FireEye and SingTel partner to launch first managed defense solution; also, announced targeted attack protection for the Apple (AAPL) platform), BCRX +2.4% (announces late breaker presentation of OPuS-1 Phase 2 Trial results at the 23rd EADV Congress will be present Oct 11), ADHD +2.3% (after yesterday's 57% decline), ACHN +1.8% (disclosed it entered into a Master Security Agreement for a $1,000,000 Capital Expenditure Line of Credit), SBLK +1.6% (collected $8.016 mln from the sale of its claim against PAN OCEAN), REGN +1.3% (EYLEA (aflibercept) Injection received FDA approval for macular edema following retinal vein occlusion), PSTI +1.3% (wins cell therapy patent case in Europe; European Patent Office confirms validity of amended claims )

Analyst comments: ADHD +2.3% (upgraded to Outperform at FBR Capital), NDLS +2.1% (upgraded to Buy from Hold at Jefferies), AUY +2.1% (upgraded to Neutral from Underweight at HSBC Securities), GMCR +1.9% (initiated with a Buy at Goldman), KPTI +1.1% (initiated with a Outperform at Wedbush), IP +1.1% (upgraded to Buy from Neutral at BofA/Merrill), CCK +0.7% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: SODA -15.1%, TCS -14.6%, EZPW -13.6%, CBK -11.8%, AEGN -9.3%, AGCO -8.7%

M&A news: RIO -1% (issues statement regarding press speculation surrounding Glencore (GLNCY))

Notable EU names showing weakness: ORAN -2.2%, DB -2.1%, NOK -2%, NBG -1.8%, RCL -1.2%, CCL -1.1%, AZN -1.1%, UBS -1.1%, LYG -0.8%, CS -0.8%

Other news: KOS -6.1% (announces secondary public offering of 15 mln common shares), BBEP -5.3% (announces public offering of 14 mln common units), END -5.3% (announced the appointment of a Chief Restructuring Officer), IBIO -4.7% (files for sale of up to 23,418,172 shares of common stock by Aspire Capital Fund), CNHI -4.3% (in sympathy with AGCO earnings), KCAP -3.8% (commences 3 mln share public offering), DYN -2.1% (launched 22.5 mln share common stock and 4 mln share mandatory convertible preferred stock offerings), NRP -2% (prices 8.5 mln common units at $12.02 per common unit), OTIV -1.6% (filed for $50 mln mixed securities shelf offering), BUD -1.6% (still checking), MBLY -1.4% (cont weakness), NUS -1% (following afternoon strength on volume)

Analyst comments: LVS -3.1% (downgraded to Hold from Buy at Deutsche Bank), URI -2.7% (downgraded to Neutral from Buy at BofA/Merrill), DE -2.6% (downgraded to Underperform from Neutral at BofA/Merrill), SAN -1.4% (downgraded to Reduce from Neutral at Nomura), CMI -1.3% (downgraded to Neutral from Buy at BofA/Merrill), ATI -1.2% (downgraded to Hold from Buy at KeyBanc Capital Mkts), USB -0.8% (downgraded to Mkt Perform from Strong Buy at Raymond James )

Оригинал статьи: gtstocks.com/analytics-07-10-2014.html

Ближайший уровень поддержки по SPY – 194.25 уровень сопротивления – 195.00



MASI смотрим на продажу с открытия

EDZ покупка выше 37

GTLS покупка выше 53

Gapping up/down: GPN +5% after earnings, WLT +6% on M&A spec, DTV +1.5% after renewed Sunday Ticket deal, TWTR +2% on upgrade at JPM; CREE -13% and AGU -5.5% after earnings/guidance, JPM -1% after dg at UBS Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: GPN +5.4%, DRI +0.8%

M&A news: WLT +5.8% (may be an acquisition target by BHP (BHP), according to reports)

Select semiconductor stocks trading higher: UMC +2%, STM +1.6%, MU +1.4%, ASML +1.4%, AMD +1.2%

Other news: ESPR +33.4% (announces positive top-line Phase 2b results for ETC-1002, an investigational therapy for patients with hypercholesterolemia ), RLD +21.9% (Starboard raises stake to 9.9% and delivered a letter to the Board proposing to acquire the company for $12 per share), ARIA +10.2% (announces AP26113 has received Breakthrough Therapy designation by the FDA), LEU +8.8% (elects Williams as Chairman; begins process for CEO Transition; Chief Restructuring Officer John Castellano named interim CEO; John Welch to step down later this month), BTU +7% (WLT peer, may be in sympathy), DRL +6.2% (provided an update on status of its capital plan: co maintains readily available liquidity sources of ~$1 bln), SPEX +5.4% (cont momentum), GRMN +5% (announces Honda (HMC) has selected Garmin as the navigation provider for future Civic and CR-V models in Europe, Russia and South America), NBG +3.8% (still checking), TSLA +3.6% (Elon Musk tweets 'About time to unveil the D and something else'; suggesting Model D introduction on Oct 9), DTV +1.4% (Co and NFL extended and expanded DIRECTV's exclusive rights to carry NFL SUNDAY TICKET), ARG +1.3% (to increase argon prices by up to 15%, effective November 1 or as contracts permit), QIHU +1.1% (announces $200 mln Share Repurchase Plan), TKMR +1% (ebola play that was +18% yesterday)

Analyst comments: NDAQ +4.4% (upgraded to Buy from Hold at Deutsche Bank), ADSK +3.3% (upgraded to Outperform from Mkt Perform at Cowen), AKS +2.9% (upgraded to Buy from Hold at Deutsche Bank), TWTR +2.3% (upgraded to Overweight from Neutral at JP Morgan), JBLU +2% (upgraded to Mkt Perform from Underperform at Raymond James), RUBI +1.6% (initiated with a Buy at B. Riley & Co), P +1.5% (upgraded to Buy at Topeka Capital Markets), THRM +0.9% (upgraded to Outperform from Mkt Perform at Barrington Research ), ICE +0.7% (upgraded to Buy from Hold at Deutsche Bank), EXXI +0.7% (upgraded to Buy from Neutral at Guggenheim), BMS +0.7% (upgraded to Neutral from Underperform at BofA/Merrill), HBI +0.6% (initiated with a Outperform at Credit Suisse), VLO +0.5% (initiated with a Outperform at RBC Capital Mkts), BAC +0.5% (upgraded to Buy from Neutral at UBS)

Gapping down
In reaction to disappointing earnings/guidance: CREE -12.9%, AGU -5.5%, STZ -2.9%

Other news: WILN -13.1% (commenced litigation against several companies), TWI -8.7% (light volume, may be attributed to AGU outlook), NLNK -5.7% (announced appointment of Jack Henneman as Chief Financial Officer following departure of Gordon H. Link, Jr.), DNDN -5.2% (still checking), PTLA -3.6% (Portola Pharma files for 10 mln share common stock shelf offering; commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000), GPRO -2.5% (cont pre-mkt vol activity), RDUS -1.7% (announces proposed public offering), RVNC -1.5% (announced expected delay in results from Phase 3 study of RT001 for the treatment of lateral canthal (crow's feet) lines), MRD -1.5% (filed for ~27.8 mln share common stock offering by selling shareholders), POT -1% (following AGU earnings)

Analyst comments: DNDN -5.2% (target cut to $1 from $2 at Citi), ENPH -2.4% (downgraded to Neutral from Buy at BofA/Merrill), JPM -1% (downgraded to Neutral from Buy at UBS), MSI -0.7% (downgraded to Neutral from Buy at Citigroup), X -0.5% (downgraded to Hold from Buy at KeyBanc Capital Mkts), ETN -0.5% (downgraded to Perform from Outperform at Oppenheimer)

Оригинал статьи: gtstocks.com/analytics-02-10-2014.html

Ближайший уровень поддержки по SPY – 197.50 уровень сопротивления – 198.25



CLVS продажа от 49

CSC смотрим на продажу

AMBA покупка выше 44.50

ETP смотрим на продолжение роста

CVEO покупка от 13

Gapping up/down: WAG +2% after earnings, MOVE +37% after merger news, TASR +4% on London Police camera news, AA +1% on upgrade; DWA -9% on downplay of takeover chatter, miners trading lower, CRR -1% on dg Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: SNX +8.1%, (also initiates quarterly cash dividend of $0.125 per common share), SCOK +7.7%, WAG +2.3%, RBS +2.1%, CTAS +1.1%, HTGC +0.8%, (on track to achieve annual new commitments of approximately $700-$850 million for 2014)

M&A news: MOVE +37% (to be acquired by News Corp (NWSA) for $21 per share), DLIA +25% (announces review of strategic alternatives; received several inquiries from third parties regarding potential acquisition of the company), MAS +7.2% (announces strategic initiatives; Co to spin-off installation and other services segment, initiate share repurchase program and reduce corporate expense), SMPL +4.9% (HomeStreet to merge with Simplicity Bancorp; Simplicity stockholders to receive one share of HomeStreet common stock for each share of Simplicity common stock)

Other news: WYY +17.8% (received two new Task Orders from federal agencies under a recently awarded Federal Government Blanket Purchase Agreement), VIMC +13.8% (announces $12.4 mln contract win in Taiyuan City of Shanxi Province), CPRX +13.7% (announces positive top-line Phase 3 Data From Pivotal Firdapse clinical trial in patients with Lambert-Eaton Myasthenic Syndrome), ACST +11.5% (announces 'Positive' top-line Pharmacokinetic results), CRNT +10.8% (receives follow-on orders from a global Tier 1 operator serving 20 countries across Asia and Africa), CANF +9.6% (USPTO issues Can-Fite patent for CF102 in the treatment of liver regeneration and function following surgery), EBAY +8.9% (eBay to separate eBay and PayPal into independent publicly traded companies in 2015), BLDP +8.2% (receives ElectraGen fuel cell system order for deployments in Digicel network), CNET +7.8% (Co's Liansuo.com signs 12 new clients following Guangzhou Franchise Exhibition), HTZ +5.4% (still checking), TASR +3.9% (selected by the London Metropolitan Police Service to provide another 500 AXON cameras), PLUG +3.4% (move attributed to positive blog mention, also peer BLDP received large order), RWLK +2.9% (cont momentum post IPO), MCP +2.4% (announces that its expanded leach system has now been placed into service at its Mountain Pass, California Facility), CTRP +2.3% (Priceline (PCLN) disclosed a 5.84% active stake in 13D filing) MBLY +2.3% (still checking), RADA +2.2% (following yesterday's 35% move higher), GPRO +1.9% (following 11% upside move yesterday), HIMX +1.8% (cont momentum), EXXI +1.5% (provides operations update: Q1 production expected at mid-point of guidance; West Delta horizontal program continues to deliver with three new wells brought online ), Z +1.4% (MOVE peer), KR +1.2% (positive commentary on Monday's Mad Money), SDRL +1.1% (still checking, may be just bouncing — shares have sold off significantly in recent weeks), AAPL +0.8% (iPhone 6 & iPhone 6 Plus available in China on Friday, October 17)

Analyst comments: TK +6.6% (upgraded to Buy from Hold at Deutsche Bank), MLNX +3.3% (upgraded to Overweight from Neutral at Piper Jaffray), RMBS +2.8% (attributed to positive Jefferies comments suggesting RMBS as Apple Pay beneficiary), EPAM +1.7% (initiated with a Positive at Susquehanna), AA +1% (upgraded to Buy from Neutral at BofA/Merrill), NWBI +1% (upgraded to Outperform from Neutral at Boenning & Scattergood), TM +0.8% (upgraded to Overweight from Neutral at JP Morgan), FB +0.7% (target raised to $95 from $90 at Evercore), LMT +0.5% (upgraded to Buy from Hold at Stifel)

Gapping down
In reaction to disappointing earnings/guidance: PDFS -17.8%, JRJC -8%, TA -5.2%, SANW -4.1%

M&A news: DWA -9.1% (Softbank (SFTBY) merger talks with DWA being donwplayed, according to reports; also reports indicate SFTBY may purchase Legendary Pictures)

Select metals/mining stocks trading lower: AU -2.1%, GFI -2%, SSRI -1.6%, AG -1.5%, IAG -1.4%, SLV -1.4%, PAAS -1.4%, FSM -1.2%, GDX -1.1%, ABX -0.9%, GLD -0.8%, SLW -0.8%

Other news: MTL -13.3% (cont bankruptcy speculation), TSL -3% (announces the offering of ~7 mln American Depositary Shares), FDUS -2.2% ( announces commencement of public offering of common stock), WUBA -1.8% (still checking), F -0.9% (following late weakness on comments from Investor Day — says it will miss its 2014 pretax profit goal of $6 bln), SVU -0.9% (announced the discovery of malware on some of its point of sale systems; protective technology believed to have limited the risk of data theft)

Analyst comments: ARMH -2.1% (downgraded to Underperform from Mkt Perform at Bernstein), CRR -1% (downgraded to Underweight from Equal-Weight at Morgan Stanley), SGEN -1% (downgraded to Underperform from Neutral at BofA/Merrill), K -0.9% (downgraded to Underweight from Equal-Weight at Morgan Stanley)

Оригинал статьи: gtstocks.com/analytics-30-09-2014.html

Ближайший уровень поддержки по SPY – 196.75 уровень сопротивления – 197.25



AGIO продажа ниже 64

NKE продажа от 89

LLL продажа от 114.75

IRM покупка выше 32

Gapping up/down: AMBI +88%, DWA +26%, ATHL +24%, TIBX +21% and AMAG +15% on M&A related news; HIMX +2% on upgrade; EU financials, select energy and metal names trading lower; AVY -1% on dg at JPM Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: RCON +7.2%, LAS +2.3%, KOOL +1.7%, CALM +1.2%, ADP +0.7%

M&A news: AMBI +87.8% (Daiichi Sankyo (DSNKY) to acquire Ambit Biosciences for $15 per share in cash through a tender offer), DWA +26.4% (Softbank (SFTBY) is in discussions to purchase DWA, according to reports, Variety discusses comments from sources that chances of Softbank (SFTBY) acquiring DWA are slim), ATHL +24.6% (Encana (ECA) to acquire all of the issued and outstanding shares of common stock of Athlon by means of an all-cash tender offer for $58.50 per share), TIBX +21% (to be acquired by Vista Equity Partners for $24.00 per share in cash), AMAG +15.4% (to acquire Lumara Health for $600 mln in cash and $75 mln in stock and additional contingent consideration of up to $350 mln)

Other news: EXEL +18.6% (announces positive results from Phase 3 pivotal trial of Cobimetinib in combination with Vemurafenib in patients with BRAF V600 Mutation-positive advanced melanoma), ALIM +16.6% (provides details on FDA approval Of ILUVIEN as the first long-term treatment for diabetic macular edema), ECYT +10.2% (Phase 2b TARGET trial results show improved survival in Adenocarcinoma non-small cell lung cancer patients treated with Endocyte's Vintafolide), PSDV +9.8% (reports approval of ILUVIEN for diabetic macular edema; triggers $25 mln milestone payment from Alimera Sciences (ALIM)), CYTR +7.9% (receives multiple FDA Orphan Drug designations for Aldoxorubicin for the treatment of Glioblastoma), PE +5.6% (still checking), ACST +4.1% (reports successful CaPre Phase II TRIFECTA results proving statistically significant improvements in triglycerides & non-HDL-C), ARIA +4% (announces updated clinical results for AP26113, study results show sustained anti-tumor activity), SGEN +3.9% (Seattle Genetics and Takeda (TKPYY) announce positive data from Phase 3 AETHERA clinical trial of ADCETRIS), KMDA +3.3% (announces second extension of Strategic Agreement with Baxter (BAX)), ISR +3.1% (still checking), DATE +3% (declared a special one-time cash dividend of $0.4467 per ordinary share, or $0.67 per American Depositary Share), WEX +1.4% (positive commentary on Friday's Mad Money)

Analyst comments: HIMX +2.2% (upgraded to Buy from Hold at Craig Hallum), SAH +1.4% (upgraded to Overweight from Underweight at Morgan Stanley), BIDU +0.7% (upgraded to Buy from Neutral at UBS)

Gapping down
In reaction to disappointing earnings/guidance: ELGX -2%, FGP -1.4%

Select EU financial related names showing weakness: HSBC -2.1%, NBG -2%, BCS -1.5%, LYG -1.4%, ING -1.3%, DB -1.1%

Select metals/mining stocks trading lower: VALE -3.6%, CLF -2.4%, X -2.1%, RIO -1.8%, BHP -1.5%

Select oil/gas related names showing early weakness: PBR -3.9%, CEO -2.2%, TOT -1%, BP -0.5%.

Other news: NXTD -8.3% (reports Wocket is in production), JNS -1.7% (slight pull back following Friday's 40%+ move higher), OLBK -1.6% (announces plans for branch consolidation), BBRY -1.3% (still checking), TSLA -1.3% (WSJ discusses that many in China are still skeptical regarding TSLA China stations), AAPL -1.2% (several stories out over weekend, may be attributed to news that AAPL may be accused of illegal Irish tax deals)

Analyst comments: EMKR -3.2% (downgraded to Hold from Buy at Needham), AVY -1.2% (downgraded to Neutral from Overweight at JP Morgan), DE -0.5% (target lowered to $95 from $98 at Credit Suisse), DRC -0.5% (downgraded to Neutral from Buy at Guggenheim)

Оригинал статьи: gtstocks.com/analytics-29-09-2014.html

Ближайший уровень поддержки по SPY – 198.40 уровень сопротивления – 198.60



CLX продажа ниже 97

UTHR продажа ниже 134

SFLY продажа ниже 50

CXO покупка выше 127

YELP при удержании 71 покупка, ниже продажа

UBNT покупка при удержании 38

Gapping up/down: SLXP +8% and CF +7% on M&A news; miners trading higher, TKMR +10% on Ebola collaboration news; ASNA -11% and KMX -6% after earnings, Tax inversion names trading lower, DKS -6% after dg Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: SUPN +9.5%, MM +1.7%, (also, to acquire Nexage for ~$107.5 mln)

M&A news: SLXP +8.2% (Allergan (AGN) plans to reject offer from Actavis (ACT) and may now bid for SLXP itself, according to reports), CF +7.2% (Yara ASA confirms discussions with CF (CF) regarding potential merger of equals)

Select metals/mining stocks trading higher: HMY +3.4%, GOLD +2.3%, SLW +1.9%, AU +1.9%, GG +1.6%, ABX +1.4%, NEM +1.4%, GDX +1.4%, GLD +1.2%, RIO +0.9%, BHP +0.8%

Other news: SYN +36% (still checking), NXTD +24.5% (cont momentum higher), TTOO +18.1% (announced FDA approval of first direct blood test for detection of five yeast pathogens that cause bloodstream infections), RWLK +11% (announces reimbursement coverage by major German insurance company ), SAEX +9.9% (announced $40 mln of new project awards), TKMR +9.6% (is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa), NAVB +7.1% (Awarded $1.67 mln Fast Track NIH SBIR Grant for Evaluation of Lymphoseek in Cervical Cancer), JRJC +6.6% (entered into a strategic partnership agreement with Zhongshan Securities), ECYT +3.6% (announces late-breaking abstract presentation on randomized, phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive non-small cell lung cancer patients at the European Society for Medical Oncology Conference), MBLY +3.4% (favorable commentary on Monday's Mad Money), HLF +2.7% (following 12%+ move lower on some chatter that Icahn is unwinding his position; after the close Gasparino tweeting that sources say Icahn has not sold any of his HLF stake), DRL +2.2% (co stated its remains confident in the rule of law and that it will prevail' as DRL vs. Hacienda trial concluded), CNET +1.9% (cont momentum), PHG +1.7% (establishes two companies in Lighting solutions and in HealthTech; sees 2H adjusted EBITA slightly below same period last year), MGA +1.7% (expands in India; targeting start of volume production in 2015), DRI +1.4% (issues open letter to shareholders; recommends darden shareholders vote 'for all' on the BLUE Proxy Card ), ASTM +1.1% (Great Point Partners discloses 9.99% stake in 13G filing), LDOS +1% (awarded contract by Naval Medical Logistics Command)

Analyst comments: SGMO +4% (initiated with a Buy at Jefferies), NRG +1.8% (resumed with a Buy at Deutsche Bank), BKU +1.6% (resumed with a Outperform at Wells Fargo), FOE +1.2% (upgraded to Buy from Hold at KeyBanc Capital Mkts), FRC +1% (resumed with a Outperform at Wells Fargo)

Gapping down
In reaction to disappointing earnings/guidance: ASNA -11.1%, ALCS -6.9%, KMX -6.3%

M&A news: BUD -1.1% (cont spec surrounding M&A)

Select Tax Inversion related names showing weakness: SHPG -5.2%, AZN -4.8%, COV -3.9%, SNN -3.7%, MDT -3.7%, ABT -3.3%, BKW -1.8%, MYL -1.8%, PFE -1.8%, PRGO -1.3%, VRX -1.1%

Other news: MTL -28.4% (continued bankruptcy concerns), AVNR -7.5% (announced offering of $200 mln of common stock), GEL -4.9% (announces public offering of 4.0 mln common units), ALIM -2.8% (disclosed sales agreement to issue and sell $35 mln common stock), TSLA -1.8% (cont weakness), YHOO -1.7% (cont weakness post BABA IPO), BABA -1.6% (cont weakness post IPO), SYY -1.5% (may face antitrust lawsuit over US Foods deal, according to reports), TOT -1.4% (trading lower in Europe following news out yesterday afternoon), HCLP -1.4% (unfavorable commentary on Monday's Mad Money)

Analyst comments: DKS -5.9% (downgraded to Mkt Perform from Outperform at William Blair ), ONNN -3.1% (downgraded to Neutral from Overweight at JP Morgan), BBBY -1.3% (downgraded to Mkt Perform from Outperform at William Blair), CLX -1.2% (downgraded to Neutral from Buy at Citigroup), GMAN -0.6% (downgraded to Hold from Buy at Canaccord Genuity)

Оригинал статьи: gtstocks.com/analytics-23-09-2014.html

Ближайший уровень поддержки по SPY – 199.85 уровень сопротивления – 200.60



CNQR смотрим на падение

COL продажа от 80

CRR смотрим на покупку от 76

MGA покупка выше 104

Gapping up/down: SIAL +35% and VIAS +30% on M&A news, ALLT +1% after securring 3 new orders; metals and miners trading lower, MTL -34% after Russia's Economy Minister suggesting bankruptcy is most likely scenario, YHOO -3% after dg's Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: LCI +1%, (also announces launch of Oxycodone Hydrochloride Oral Solution)

M&A news: SIAL +34.9% (Germany's Merck KGaA (MKGAY.PK) to acquire SIAL for $140 per share in cash), VIAS +30.3% (TTM (TTMI) will acquire Viasystems for a combined consideration of $11.33 in cash and 0.706 shares of TTM common stock, or $16.46/share), VSI +2.7% (positive mention in Barron's suggesting the company as possible takeover target), CLX +2.7% (rejected takeover offer at 20% premium prior to news CEO will step down, according to reports), EMC +1.8% (may have had merger related discussions with HP (HPQ), according to reports)

Other news: CNET +6.6% (cont strength), TATT +5.3% (signed a seven year landing gear Maintenance Support Agreement with Republic Airways Holdings (RJET)), DRL +3.8% (states that after two days of trial, Hacienda has put forth no evidence), RSH +3.3% (had discussions with a major vendor concerning potential modifications to the commercial relationship), TTM +2.8% (still checking), INO +2.7% (expands HPV Immunotherapy development to aerodigestive cancers), DRC +2.1% (signs agreement to sell to Siemens (SIEGY) for $83.00 per share in cash), ALLT +1.4% (secures three orders from major cloud providers), ADHD +1% (announces completion of all patient visits in Phase 3 clinical trial of MDX in adult ADHD), AAL +1% (American Airlines and the Association of Professional Flight Attendants reach tentative agreement)

Analyst comments: ORBC +0.8% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: TRS -3%, (lowered FY14 EPS guidance; announced acquisition of Allfast Fastening Systems for $360 mln)

M&A news: AUXL -0.8% (provides transaction update; unanimously determined unsolicited, non binding offer from Endo Intl (ENDP) is not a superior proposal under the terms of its existing merger agreement with QLT (QLTI))

Select metals/mining stocks trading lower: RIO -2.2%, VALE -2%, BHP -1.8%, IAG -1.6%, SLV -1%, MT -0.7%

Other news: MTL -34.5% (reports of Russia's Economy Minister suggesting bankruptcy is most likely scenario), COCO -6.3% (received a grand jury subpoena for documents in Florida and Georgia), CRR -5.3% (provides marketplace update), STM -3.7% (still checking), ECTE -3.5% (Newly elected Board members to host conference call to provide shareholder update on Monday, September 22), AMRN -3.1% (may be in symp with INVN dg), ACHN -3% (may be in symp with INVN dg), CRDS -2.6% (files registration statement for proposed offering of Series H preferred stock and warrants to purchase common stock), CNHI -2% (announces plans to issue notes denominated in Euro), TSLA -1.2% (still checking; may be attributed to JPM comments preferring F and GM shares)

Analyst comments: INVN -3.3% (downgraded to Neutral from Outperform at Robert W. Baird), YHOO -3.1% (downgraded to Neutral from Buy at BofA/Merrill, to Mkt Perform from Outperform at Bernstein), RLGY -2.1% (downgraded to Underperform from Neutral at Credit Suisse), LVS -1.7% (downgraded to Market Perform from Outperform at Wells Fargo), VMI -1.5% (downgraded to Neutral from Buy at Sterne Agee), LNN -1.1% (downgraded to Neutral from Buy at Sterne Agee), WAG -0.9% (downgraded to Equal Weight from Overweight at Barclays), WYNN -0.8% (downgraded to Market Perform from Outperform at Wells Fargo), MPEL -0.8% (downgraded to Market Perform from Outperform at Wells Fargo).

Оригинал статьи: gtstocks.com/analytics-22-09-2014.html